Bipolar disorder and the risk of developing dementia - a systematic review and meta-analysis.

Curr Opin PsychiatryMay 20, 2026 (epub)
Clinical ResearchPsychiatry

Lars Vedel Kessing, Klaus Munkholm

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the risk of dementia in patients with bipolar disorder, analyzing data from 22 studies involving 185,306 patients with bipolar disorder and 10,702,744 without. The findings indicated a significantly increased risk of dementia in bipolar patients, with an odds ratio of 3.13 (95% CI: 2.40-4.09).

Key findings

  • Patients with bipolar disorder have an odds ratio of 3.13 for developing dementia compared to those without.
  • In a secondary analysis, the odds ratio was 2.60 when excluding studies with overlapping populations.
  • The analysis included 21 studies contributing to the meta-analysis.
  • Substantial heterogeneity was noted among the studies included.

Why it matters

Understanding the increased risk of dementia in patients with bipolar disorder is crucial for clinicians, as it may influence monitoring and management strategies for this population.

What to keep in mind

The evidence was uncertain due to substantial and unexplained between-study heterogeneity, methodological limitations, and risk of bias.

Source

PubMed · PMID 42233646

Published in Curr Opin Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.